| Literature DB >> 36097276 |
Mizuki Ohashi1,2, Shunichiro Tsuji3, Sachiko Tanaka-Mizuno2,4, Kyoko Kasahara1, Makiko Kasahara1, Katsuyuki Miura2,5, Takashi Murakami1.
Abstract
We aimed to evaluate the changes in maternal and neonatal complications such as threatened preterm labor (TPL) and preterm birth before and during the coronavirus disease 2019 (COVID-19) pandemic using large-scale real-world data in Japan. We obtained data from the Japan Medical Data Center claims database and evaluated differences in maternal and neonatal complications, such as the prevalence of TPL and preterm birth before the COVID-19 pandemic (in the year 2018 or 2019) and during the COVID-19 pandemic (in 2020). We included 5533, 6257, and 5956 deliveries in the years 2018, 2019, and 2020, respectively. TPL prevalence and preterm birth had significantly decreased in 2020 (41.3%, 2.6%, respectively) compared with those reported in 2018 (45.3%, 3.9%, respectively) and 2019 (44.5%, 3.8%, respectively). Neonatal outcomes such as low-birth-weight infants and retinopathy of prematurity were also improved during the pandemic. There were no clear trends in the prevalence of maternal complications such as hypertensive disorders of pregnancy; hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome; and preeclampsia. Oral ritodrine hydrochloride usage in all participants had significantly decreased during the COVID-19 pandemic. In conclusion, our results suggest that the COVID-19 pandemic has ameliorated TPL and consequently reduced the number of preterm births.Entities:
Mesh:
Year: 2022 PMID: 36097276 PMCID: PMC9467430 DOI: 10.1038/s41598-022-19423-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Figure 1Flow chart of the study population. We firstly extracted delivery information from October to December between 2018 and 2020 from the database. The numbers of participants were shown based on deliveries and newborns. We defined the deliveries in 2018 and 2019 as before the COVID-19 pandemic and the deliveries in 2020 as during the COVID-19 pandemic. TPL was diagnosed by ICD-10 code and the use of tocolytic agents, which records were used to analyze each medical use and dosage. COVID-19 Coronavirus disease 2019, TPL threatened preterm labor.
Maternal characteristics and complications during pregnancy among the 17,746 deliveries in the years 2018, 2019, and 2020.
| Year of childbirth | |||||||
|---|---|---|---|---|---|---|---|
| Before COVID-19 pandemic | During COVID-19 pandemic | ||||||
| 2018 | 2019 | p-valuea | 2020 | p-valueb | p-valuec | ||
| Number of deliveries (n) | 5533 | 6257 | 5956 | ||||
| Childbirths of singleton (n, %) | 5469 (98.8) | 6177 (98.7) | 0.548 | 5892 (98.9) | 0.675 | 0.296 | |
| Mother's age at childbirth | 32.6 (4.6) | 32.8 (4.6) | 0.112 | 32.8 (4.6) | 0.038 | 0.601 | |
| Hypertension (n, %) | 97 (1.8) | 110 (1.8) | 0.984 | 108 (1.8) | 0.808 | 0.818 | |
| Diabetes (n, %) | 191 (3.5) | 212 (3.4) | 0.849 | 204 (3.4) | 0.937 | 0.911 | |
| Anti-phospholipid antibody syndrome (n, %) | 31 (0.6) | 54 (0.9) | 0.053 | 39 (0.7) | 0.515 | 0.186 | |
| Threatened preterm labor (n, %) | 2507 (45.3) | 2781 (44.5) | 0.347 | 2458 (41.3) | < 0.001 | < 0.001 | |
| Use of ritodrine (n, %) | 1797 (32.5) | 2014 (32.2) | 0.737 | 1722 (28.9) | < 0.001 | < 0.001 | |
| Use of magnesium sulfate (n, %) | 107 (1.9) | 128 (2.1) | 0.665 | 111 (1.9) | 0.783 | 0.468 | |
| Preterm birth (n, %) | 218 (3.9) | 238 (3.8) | 0.690 | 154 (2.6) | < 0.001 | < 0.001 | |
| Hypertensive disorders of pregnancy (n, %) | 302 (5.5) | 414 (6.6) | 0.009 | 410 (6.9) | 0.002 | 0.556 | |
| HELLP syndrome (n, %) | 7 (0.13) | 9 (0.14) | 0.799 | 2 (0.03) | 0.098 | 0.042 | |
| Preeclampsia (n, %) | 249 (4.5) | 341 (5.5) | 0.018 | 329 (5.5) | 0.012 | 0.858 | |
| Emergency transfer (n, %) | 128 (2.3) | 154 (2.5) | 0.600 | 146 (2.5) | 0.628 | 0.972 | |
| Cesarean section (n, %) | 1206 (21.8) | 1440 (23.0) | 0.114 | 1284 (21.6) | 0.757 | 0.053 | |
The denominator for the percentage is the number of deliveries. Mother’s age at childbirth is presented as mean (standard deviation).
P-values of Pearson’s chi-square test or Student’s t-test a: between 2018 and 2019, b: between 2018 and 2020, and c: between 2019 and 2020 are shown. We used a P value of 0.0167 to indicate significance to correct for multiplicity.
Neonatal characteristics and complications among the 17,957 newborns that were born in the years 2018, 2019, and 2020.
| Year of childbirth | ||||||
|---|---|---|---|---|---|---|
| Before COVID-19 pandemic | During COVID-19 pandemic | |||||
| 2018 | 2019 | p-valuea | 2020 | p-valueb | p-valuec | |
| Number of newborns (n) | 5597 | 6339 | 6021 | |||
| Preterm birth (n, %) | 218 (3.9) | 238 (3.8) | 0.690 | 154 (2.6) | < 0.001 | < 0.001 |
| Admission to neonatal intensive care unit (n, %) | 190 (3.4) | 251 (4.0) | 0.103 | 168 (2.8) | 0.060 | < 0.001 |
| Respiratory distress syndrome (n, %) | 413 (7.4) | 549 (8.7) | 0.010 | 395 (6.6) | 0.083 | < 0.001 |
| Respiratory support (n, %) | 178 (3.2) | 242 (3.8) | 0.059 | 159 (2.6) | 0.083 | < 0.001 |
| Use of artificial pulmonary surfactant (n, %) | 39 (0.7) | 58 (0.9) | 0.185 | 35 (0.6) | 0.434 | 0.032 |
| Low birth weight (n, %) | 330 (5.9) | 353 (5.6) | 0.442 | 224 (3.7) | < 0.001 | < 0.001 |
| Retinopathy of prematurity (n, %) | 37 (0.7) | 41 (0.7) | 0.923 | 14 (0.2) | < 0.001 | < 0.001 |
The denominator for the percentage is the number of newborns.
P-values of Pearson’s chi-square test, a: between 2018 and 2019, b: between 2018 and 2020, and c: between 2019 and 2020 are shown. We used a P value of 0.0167 to indicate significance to correct for multiplicity.
Use of tocolytic agents in 2018, 2019, and 2020 among all deliveries and cases with threatened preterm labor.
| Year of childbirth | ||||||
|---|---|---|---|---|---|---|
| Before COVID-19 pandemic | During COVID-19 pandemic | |||||
| 2018 | 2019 | p-valuec | 2020 | p-valued | p-valuee | |
| Number of deliveries (n) | 5533 | 6257 | 5956 | |||
| Use of ritodrine for oral administrationa (n, %) | 1720 (31.1) | 1911 (30.5) | 0.523 | 1626 (27.3) | < 0.001 | < 0.001 |
| Use of ritodrine for intravenous administrationa (n, %) | 364 (6.6) | 424 (6.8) | 0.668 | 396 (6.7) | 0.880 | 0.778 |
| Number of threatened preterm labor cases (n) | 2507 | 2781 | 2458 | |||
| Use of ritodrine hydrochloride | ||||||
| For oral administrationb (n, %) | 1720 (68.6) | 1911 (68.7) | 0.932 | 1626 (66.2) | 0.065 | 0.048 |
| Dosage for oral administration (tablets per delivery) | 63.0 (28.0, 141.0) | 63.0 (28.0, 133.0) | 0.263 | 62.5 (21.0, 132.0) | 0.064 | 0.430 |
| For intravenous administrationb (n, %) | 364 (14.5) | 424 (15.3) | 0.459 | 396 (16.1) | 0.120 | 0.390 |
| Dosage for intravenous administration (ampoules per delivery) | 21.5 (6.5, 66.0) | 20.0 (6.0, 58.0) | 0.290 | 22.0 (6.0, 62.0) | 0.663 | 0.573 |
| Use of magnesium sulfateb (n, %) | 84 (3.4) | 83 (3.0) | 0.447 | 78 (3.2) | 0.725 | 0.693 |
| Dosage of magnesium sulfate (ampoules per delivery) | 8.0 (4.0, 32.0) | 7.0 (3.0, 31.0) | 0.787 | 8.0 (4.0, 37.0) | 0.507 | 0.283 |
| Threatened preterm labor treated in larger medical institutions (≥ 20 beds)b (n, %) | 1153 (46.0) | 1250 (45.0) | 0.447 | 1075 (43.7) | 0.110 | 0.378 |
Uses of medicines are described in number (a: % for the number of deliveries, b: % for the number of threatened preterm labor cases), and their dosages are described in median (25th percentile, 75th percentile).
P-values of Pearson’s chi-square test or Wilcoxon’s rank sum test c: between 2018 and 2019, d: between 2018 and 2020, and e: between 2019 and 2020 are shown. We used a P value of 0.0167 to indicate significance to correct for multiplicity.